Labcorp Holdings Inc. (LH) News
Track canonical SquawkNews coverage tagged to LH, Labcorp Holdings Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 42 indexed stories across 17 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Diagnostic-testing stocks drop after proposed Medicare lab payment cuts
Labcorp and Quest Diagnostics shares fell in premarket after CMS proposed cuts to Medicare payment rates for laboratory services.
EQUITY | Sep 22, 2026, 01:10 PM UTC
H
LH: Reaffirmed strong growth outlook, driven by specialty testing, tech, and strategic acquisitions
Long-term guidance through 2026 was reaffirmed, with strong revenue and EPS growth targets, margin expansion, and robust free cash flow. Specialty testing, technology investments, and acquisitions are key growth drivers,
EARNINGS | Sep 15, 2026, 05:10 PM UTC
H
LH: Reaffirmed 2026 guidance highlights specialty testing, AI, and acquisitions as key growth drivers
Long-term guidance through 2026 was reaffirmed, with strong revenue and EPS growth targets, margin expansion, and robust free cash flow. Specialty testing, technology investments, and acquisitions are key growth drivers,
EARNINGS | Sep 15, 2026, 04:37 PM UTC
M
Labcorp outlines 2026 guidance and long-term outlook
Labcorp reaffirmed 2026 guidance and gave a 2026-2029 outlook targeting 5%-8% revenue CAGR and 8.5%-11.5% adjusted EPS CAGR. It also cited $18.10-$18.55 in 2026 adjusted EPS guidance.
EARNINGS | Sep 10, 2026, 08:54 PM UTC
M
Labcorp presents 2026 guidance and 2029 growth targets
Labcorp Holdings reaffirmed full-year 2026 adjusted EPS guidance of $18.10 to $18.55 and sales guidance of $14.710 billion to $14.827 billion at its 2026 Investor Day. The company also outlined 2029 targets for 5% to 8%
EARNINGS | Sep 10, 2026, 05:40 PM UTC
H
Labcorp backs guidance: EPS $18.10–$18.55, revenue $14.71B+
Labcorp backed its year guidance and projected further gains ahead as it expects to outperform the laboratory services market. The company said it continues to expect adjusted earnings per share of $18.10 to $18.55 and r
EARNINGS | Sep 10, 2026, 01:01 PM UTC
H
Labcorp provides outlook through 2029 and reaffirms 2026 guidance
Labcorp issued its outlook through 2029. The company expects compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by end-2029, and compound annual adjusted EPS growth
EARNINGS | Sep 10, 2026, 11:32 AM UTC
H
Labcorp reaffirms outlook through 2029 with 5%-8% revenue CAGR
Labcorp reaffirms full-year 2026 guidance and provided a long-term outlook through 2029. It expects compound annual revenue growth of 5% to 8% and compound annual adjusted EPS growth of 8.5% to 11.5%.
EARNINGS | Sep 10, 2026, 11:16 AM UTC
H
Labcorp affirms FY2026 adj EPS guidance at $18.10-$18.55
Labcorp Holdings (LH) affirmed FY2026 adjusted EPS guidance of $18.10–$18.55 versus a $18.01 analyst estimate. It also affirmed FY2026 sales guidance of $14.710B–$14.827B versus a $14.707B estimate.
EARNINGS | Sep 10, 2026, 11:11 AM UTC
H
Labcorp sees 2026 free cash flow at $1.24B-$1.36B
EARNINGS | Sep 10, 2026, 11:08 AM UTC
L
Labcorp Holdings Backs 2026 View of Rev $14.71B-$14.83B >LH
Labcorp Holdings Backs 2026 View of Rev $14.71B-$14.83B >LH
EQUITY | Sep 10, 2026, 11:07 AM UTC
H
Labcorp Sees Adjusted Operating Margin Expansion of 75-150 Basis Points by End of 2029 >LH
Labcorp Sees Adjusted Operating Margin Expansion of 75-150 Basis Points by End of 2029 >LH
EARNINGS | Sep 10, 2026, 11:07 AM UTC
H
Labcorp Holdings Sees Compound Annual Revenue Growth of 5%-8% Through 2029 >LH
Labcorp Holdings Sees Compound Annual Revenue Growth of 5%-8% Through 2029 >LH
EARNINGS | Sep 10, 2026, 11:06 AM UTC
L
LH - Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
LH - Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
EQUITY | Sep 10, 2026, 11:01 AM UTC
H
Labcorp Holdings Reaffirms Full-Year 2026 Guidance >LH
Labcorp Holdings Reaffirms Full-Year 2026 Guidance >LH
EQUITY | Sep 10, 2026, 11:01 AM UTC
L
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
BURLINGTON, N.C., Sept. 10, 2026 // -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m. ET, where the company will provide an in-dept
EQUITY | Sep 10, 2026, 11:01 AM UTC
H
Labcorp sees FY adjusted EPS range $18.10–$18.55
EARNINGS | Sep 10, 2026, 11:00 AM UTC
L
NYSE pre-market daily advisory issued for upcoming trading
NYSE issued a pre-market daily advisory direct from the NYSE Trading Floor, providing a daily update ahead of the trading session.
EQUITY | Sep 09, 2026, 12:55 PM UTC
M
Labcorp Holdings to acquire MLM Medical Labs
Labcorp Holdings (LH) announced it has acquired MLM Medical Labs, a central and specialty laboratory provider operating across the United States, Germany and South Africa. Financial terms were not disclosed.
MNA | Sep 08, 2026, 01:59 PM UTC
M
Labcorp to acquire MLM Medical Labs, expanding clinical trial labs
Labcorp will acquire MLM Medical Labs to expand its global central laboratory and biomarker capabilities for clinical trials.
EQUITY | Sep 08, 2026, 01:06 PM UTC
L
Labcorp to present executives at Morgan Stanley global healthcare conference Sept. 15
Labcorp said it will present executives at the Morgan Stanley Global Healthcare Conference on Sept. 15. A webcast will be available.
EQUITY | Aug 28, 2026, 12:44 PM UTC
L
Labcorp to speak at Morgan Stanley Global Healthcare Conference
Labcorp said it will speak at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Aug 28, 2026, 12:30 PM UTC
L
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Aug 28, 2026, 12:30 PM UTC
M
Labcorp to offer first FDA-cleared blood test for Alzheimer’s pathology
Labcorp says it will offer the first FDA-cleared blood test to detect Alzheimer’s disease pathology in both primary and specialty care settings.
REGULATION | Aug 24, 2026, 11:04 AM UTC
L
LabCorp plans nationwide availability of test in coming months
LabCorp says it plans nationwide availability of a test in coming months, without providing the test name, timing details, or catalyst.
EQUITY | Aug 24, 2026, 11:03 AM UTC
M
LabCorp to offer first FDA-cleared Alzheimer’s blood test
LabCorp says it will offer the first FDA-cleared blood test to detect Alzheimer’s disease pathology in both primary and specialty care settings.
EQUITY | Aug 24, 2026, 11:03 AM UTC
L
Labcorp (LH) and NACHC launch strategic alliance
Labcorp (LH) and NACHC launch a strategic alliance focused on strengthening health center leadership and advancing community health.
REGULATION | Aug 18, 2026, 11:00 AM UTC
L
Labcorp (LH) to Host Investor Day on September 10, 2026
Labcorp (LH) will host an investor day on September 10, 2026, according to the company’s announcement; no additional agenda, guidance, or catalyst details were supplied.
EQUITY | Aug 17, 2026, 12:01 PM UTC
L
LH - Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
LH - Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
REGULATION | Aug 10, 2026, 11:01 AM UTC
L
LH - Labcorp Launches FDA -Approved PTEN Companion Diagnostic for Prostate Cancer
LH - Labcorp Launches FDA -Approved PTEN Companion Diagnostic for Prostate Cancer
REGULATION | Aug 04, 2026, 11:01 AM UTC
M
JP Morgan raises LH PT to $360
JP Morgan raises LH price target
EQUITY | Aug 03, 2026, 09:58 AM UTC
M
LabCorp: ACA Changes To Impact 2026 Diagnostics Volume
LabCorp expects 30 basis points impact on 2026 Diagnostics volume
EQUITY | Jul 30, 2026, 01:29 PM UTC
M
LabCorp: Oncology Patients Drive Higher Test Volumes
LabCorp sees higher test volumes from oncology patients
EQUITY | Jul 30, 2026, 01:29 PM UTC
M
LabCorp: Specialty Testing Grows Faster
LabCorp's specialty testing grows faster
EQUITY | Jul 30, 2026, 01:28 PM UTC
H
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650
Labcorp Holdings (NYSE: LH ) raises FY2026 Adj EPS guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 analyst estimate. Raises FY2026 sales outlook from $14.650 billion-$14.800 billion to $14.710 billion-$14.827 bill
EARNINGS | Jul 30, 2026, 10:51 AM UTC
H
LH LabCorp RESULTS: Q2, Q2 REV $3.730B vs. EST $3.711B, Q2 ADJ EPS from cont ops $4.99, Q2 EPS from cont ops $3.64, LabCorp Earnings Notes:,
LH LabCorp RESULTS: Q2, Q2 REV $3.730B vs. EST $3.711B, Q2 ADJ EPS from cont ops $4.99, Q2 EPS from cont ops $3.64, LabCorp Earnings Notes:, Outlook FY REV $14,710-14.827B vs. EST $14.707B, Outlook FY REV growth 5.4-6.3%
EARNINGS | Jul 30, 2026, 10:51 AM UTC
H
LH - Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
LH - Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
EARNINGS | Jul 30, 2026, 10:50 AM UTC
L
LH LabCorp launches Marker by labcorp™ genetic health panel, expanding consumer access to hereditary genetic risk testing
LH LabCorp launches Marker by labcorp™ genetic health panel, expanding consumer access to hereditary genetic risk testing
EQUITY | Jul 27, 2026, 12:02 PM UTC
L
Update: Labcorp to Pay $14.5 Million to Settle False Claims Act Allegations
() -- (Updates to add company's comment in paragraph 5 and 6) Labcorp (LH) agreed to pay $14.5 million to resolve allegations that it violated the False Claims Act by submitting false claims to Medicare Part B for medica
EQUITY | Jul 16, 2026, 12:04 AM UTC
L
Labcorp to Pay $14.5 Million to Settle False Claims Act Allegations
() -- Labcorp (LH) agreed to pay $14.5 million to resolve allegations that it violated the False Claims Act by submitting false claims to Medicare Part B for medically unnecessary urine drug testing conducted under a tes
EQUITY | Jul 15, 2026, 10:05 PM UTC
M
LH Launches ColoSense
Labcorp launches nationwide availability of ColoSense, its RNA-based, at-home colorectal cancer screening test
EQUITY | Jun 22, 2026, 11:25 AM UTC
H
LH Launches ColoSense
Labcorp announces nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test
EQUITY | Jun 22, 2026, 11:03 AM UTC